During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Paul G. Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, Should we use melflufen to treat relapsed patients with poor prognosis?
Richardson discusses promising data from the HORIZON trial evaluating melflufen, a highly lipophilic peptide-drug conjugate, in patients with relapsed/refractory myeloma. Richardson then discusses preliminary data from the ANCHOR study, evaluating melflufen in combination with dexamethasone, and either daratumumab or bortezomib, in patients with relapsed/refractory myeloma.